CTLA4 and melanoma: In the B16F10 melanoma model, directing anti-CTLA4 and anti-PD-1 treatment to the TDLN reduces the risk of immune-related adverse events, reduces distant metastases and recurrence, and enhances the anti-cancer T cell repertoire (233).